12:00 AM
Jun 18, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

BM32: Phase IIa data

Top-line data from a double-blind, placebo-controlled, Austrian Phase IIa trial in 70 patients with grass pollen allergy showed that 3 injections of once-monthly subcutaneous BM32 significantly reduced nasal allergy symptoms induced by a grass pollen inhalation challenge at 4 weeks...

Read the full 176 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >